Cetuximab (C225) is a humanIgG1monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with aK_dof 0.201 nM forEGFRby SPR. Cetuximab has potent antitumor activity^[1].

Cetuximab (C225) is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a K_dof 0.201 nM for soluble EGFR by SPR. Cetuximab also exhibits a K_dof 0.147 nM for EGFR in fixed A431 cells by ELISA^[1]. Cetuximab (C225; 30 nM) time-dependently inhibits the proliferation of SCC-1, SCC-11B, SCC-38, and SCC-13Y cells after treatment for 8 d. Cetuximab (30 nM) causes G₀/G₁arrest, induces apoptosis, and reduces Rb, p27^KIP1, Bcl-2, and Bax expression in SCC-13Y cells. Cetuximab (30 nM) also enhances radiosensitivity and increases radiation-induced apoptosis in SCC-13Y cells^[3].

Cetuximab (1 mg/injection) has effect on the tumour volume but the effect is more pronounced on UT-SCC-14 xenografts. In UT-SCC-14 xenografts, Cetuximab treatment significantly reduces the expression of EGFR, pEGFR and Ki67. The MCT1 and GLUT1 expression is significantly decreased in the Cetuximab-treated groups of both cell lines but differences are more pronounced in UT-SCC-14 xenografts^[2].

145543.35

Liquid

205923-56-4

西妥昔单抗

Please store the product under the recommended conditions in the Certificate of Analysis.